Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib
Oncology · 2024
DOI: 10.1159/000540438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Mio Tsuruoka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan, ytrsb237@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Cell-free DNA (cfDNA) is expected to contribute to the decision for treatment and prediction of effects with minimally invasion. We investigated the correlation between gene mutations before and after lenvatinib (LEN) treatment and its effectiveness, in order to find advanced hepatocellular carcinoma (HCC) patients who would benefit greatly from the therapy.
Methods
We analyzed cfDNA before and 6–8 weeks after the start of treatment in 20 advanced HCC patients who started LEN. A next-generation sequencer was used for CTNNB1 and TP53. Concerning TERT promoter, −124C>T and −146C>T mutations are researched using digital PCR. In addition, we examined liver tumor biopsy tissues by the same method. Computerized tomography evaluation was performed at 6–8 weeks and 3–4 months to assess the efficacy.
Results
Frequencies of TERT promoter, CTNNB1, and TP53 mutations in pretreatment cfDNA were 45%, 65%, and 65%, but 53%, 41%, and 47% in HCC tissues, respectively. There were no clear correlations between these gene mutations and the disease-suppressing effect or progression-free survival. Overall, there were many cases showing a decrease in mutations after LEN treatment. Integrating the reduction of CTNNB1 and TP53 genetic mutations increased the potential for disease suppression.
Conclusion
This study suggests that analysis of cfDNA in advanced HCC patients may be useful for identifying LEN responders and determining therapeutic efficacy. Furthermore, it has potential for selecting responders for other molecular-targeted drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan, ytrsb237@gmail.com.
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Zitieren
APA
Tsuruoka, M., Ninomiya, M., Inoue, J., Iwata, T., Sano, A., Sato, K., Onuki, M., Sawahashi, S., & Masamune, A. (2024). Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib. Oncology. https://doi.org/10.1159/000540438
Vancouver
Tsuruoka M, Ninomiya M, Inoue J, Iwata T, Sano A, Sato K, et al. Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib. Oncology. 2024. doi:10.1159/000540438
BibTeX
@article{Tsuruoka2024,
author = {Tsuruoka, Mio and Ninomiya, Masashi and Inoue, Jun and Iwata, Tomoaki and Sano, Akitoshi and Sato, Kosuke and Onuki, Masazumi and Sawahashi, Satoko and Masamune, Atsushi},
title = {Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib},
journal = {Oncology},
year = {2024},
doi = {10.1159/000540438}
}
EUVIMED